Vitality Biopharma Scientific Co-Founder to Present Recent Data at CannMed Medical Conference in Los Angeles

Dr. Brandon Zipp to discuss outlook for Vitality’s VBX-100 THC prodrug in scientific presentation held at UCLA

Los Angeles, California, UNITED STATES

LOS ANGELES, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that Dr. Brandon Zipp will give a scientific presentation about VBX-100, Vitality’s proprietary THC prodrug, at CannMed 2018 in Los Angeles, CA. 

Dr. Brandon Zipp is the Director of Research & Development, as well as a Scientific Co-founder of Vitality Biopharma, and he will give a presentation at the CannMed 2018 Conference at the UCLA Luskin Conference Center on Tuesday, October 23rd, in a talk about Vitality’s lead drug candidate titled: "VBX-100: A GI-targeted Prodrug of THC for Inflammatory Bowel Disease."  In the same session, there will be a presentation by Dr. Raphael Mechoulam, a pioneering researcher that first identified THC and other cannabinoids in Cannabis sativa, as well as additional researchers presenting their latest findings on the therapeutic potential of targeting the endocannabinoid system. 

Vitality’s VBX-100 is a GI-targeted oral prodrug of Δ9-tetrahydrocannabinol (THC) intended to be functionally inert after ingestion and until it is activated in the lower gastrointestinal tract. Once the VBX-100 prodrug releases THC, it can exert therapeutic effects directly, and data indicates there is minimal systemic absorption.  As a result, there is minimal entry of THC into the bloodstream or brain, meaning it may avoid psychoactivity while also avoiding the adverse systemic effects of currently marketed immunosuppressants used widely for treatment of autoimmune conditions.  VBX-100 is being developed initially for treatment of inflammatory bowel disease (Crohn’s disease and ulcerative colitis), irritable bowel syndrome, and narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.   

“It’s exciting to share our most recent work with the cannabinoid research community and with the public,” said Dr. Brandon Zipp, Director of Research & Development and Scientific Co-Founder of Vitality Biopharma.  Dr. Zipp adds that, “We have made significant advances in 2018 and expect this conference to be an important event for the Company.”

About CannMed 2018 Conference
CannMed 2018 is a gathering of the greatest minds in medical cannabis, where they will further the convergence of medical cannabis research, treatment, and product development. The world’s top medical cannabis researchers will present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis. Clinicians will share compelling case studies and clinical pearls they have collected through their experience treating patients with cannabis. Cannabis industry leaders will also share how they are adopting innovative testing methods and technologies to create new products that move the industry forward. Find out more:

About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: Follow us on Facebook, Twitter and LinkedIn.               

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Vitality Biopharma
Investor Relations